Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephradine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC15A1 | P46059 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephradine SCHEMBL11236409 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL11236414 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL16072830 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL13779346 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL20969062 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL11209915 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL719332 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL956675 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL3128777 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL28758599 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22194 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| CN-120699943-B | Penicillin acylase for synthesizing beta-lactam antibiotics | 浙江师范大学行知学院 | 2026-05-15 | — | — | CN | claimed |
| US-20260124224-A1 | USE OF COMBINED COMPOSITION IN PREPARING DRUG FOR RESISTING FUNGAL AND BACTERIAL INFECTIONS | NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (CN) | 2026-05-07 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| EP-0052962-A1 | Pharmaceutical compositions containing two beta-lactam derivatives | BEECHAM GROUP PLC (GB) | 1982-06-02 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| US-4252786-A | POLYVINYLPYRROLIDONE WITH CARBOXYVINYL HYDROPHILIC POLYMER, INSOLUBLE BUT RUPTURABLE FILM | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | claimed |
| US-4235900-A | Cephradine compositions | E. R. SQUIBB & SONS, INC. (US) | 1980-11-25 | — | — | US | claimed |
| EP-0008525-A2 | Pharmaceutical compositions and process for their preparation | BEECHAM GROUP PLC (GB) | 1980-03-05 | — | — | EP | claimed |
| US-4143134-A | BACTERICIDES, ANTIBIOTIC POTENTIATORS | HOFFMANN-LA ROCHE INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4139702-A | Process for preparing cephalosporines | DOBFAR S.P.A. (IT) | 1979-02-13 | — | — | US | claimed |
| US-4073687-A | PENICILLINS OR CEPHALOSPORINS | SHIONOGI & CO., LTD. (JA) | 1978-02-14 | — | — | US | claimed |
| US-4028355-A | Cephalosporin purification process | SMITHKLINE CORPORATION (US) | 1977-06-07 | — | — | US | claimed |
| US-3940483-A | Antibiotic compositions and method | E. R. SQUIBB & SONS, INC. (US) | 1976-02-24 | — | — | US | claimed |